Endocrine-Related Cancer

Aims & Scope

Endocrine-Related Cancer is an official flagship journal of the Society for Endocrinology and is endorsed by the European Society of Endocrinology, the United Kingdom and Ireland Neuroendocrine Society, and the Japanese Hormones and Cancer Society.

Endocrine-Related Cancer provides a unique international forum for the publication of high quality original articles describing novel, cutting edge basic laboratory, translational and clinical investigations of human health and disease focusing on endocrine neoplasias and hormone-dependent cancers; and for the publication of authoritative review articles in these topics.

Endocrine neoplasias include adrenal cortex, breast, multiple endocrine neoplasia, neuroendocrine tumours, ovary, prostate, paraganglioma, parathyroid, pheochromocytoma pituitary, testes, thyroid and hormone-dependent cancers.

Neoplasias affecting metabolism and energy production such as bladder, bone, kidney, lung, and head and neck, are also considered.

View Aims & Scope

---

Metrics & Ranking

Impact Factor

Year	Value
2025	4.6
2024	4.10

Journal Rank

Year	Value
2024	1977

Journal Citation Indicator

Year	Value
2024	1197

SJR (SCImago Journal Rank)

Year	Value
2024	1.674

Quartile

Year	Value
2024	Q1

h-index

Year	Value
2024	149

---

---

Abstracting & Indexing

Journal is indexed in leading academic databases, ensuring global visibility and accessibility of our peer-reviewed research.

• Scopus
• Google Scholar
• Web of Science
• Medline
• Embase

---

Subjects & Keywords

Journal’s research areas, covering key disciplines and specialized sub-topics in Biochemistry, Genetics and Molecular Biology and Medicine, designed to support cutting-edge academic discovery.

---

Most Cited Articles

The Most Cited Articles section features the journal's most impactful research, based on citation counts. These articles have been referenced frequently by other researchers, indicating their significant contribution to their respective fields.

• BRAF mutation in thyroid cancer

  Citation: 1019

  Authors: M

• Fibroblast growth factors, their receptors and signaling.

  Citation: 1015

  Authors: C J, S W, A

• Diabetes and cancer

  Citation: 848

  Authors: Paolo, Francesco, Laura, Giuseppe, Riccardo

• Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients

  Citation: 664

  Authors: Balázs, András, Zoltán

• The role of let-7 in cell differentiation and cancer

  Citation: 543

  Authors: Benjamin, Sun-Mi, Annika, Andrea E, Marcus E

• The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification.

  Citation: 506

  Authors: N, O M, S, S, A

• Highly prevalent TERT promoter mutations in aggressive thyroid cancers

  Citation: 505

  Authors: Xiaoli, Justin, Yuan, Sara, Dingxie, Avaniyapuram Kannan, Hui, Adel K, Mingzhao

• Mechanisms of tamoxifen resistance

  Citation: 481

  Authors: Alistair, Mitch

• Resveratrol and cancer: focus on in vivo evidence

  Citation: 421

  Authors: Lindsay G, John A, Kevin J

• Postmenopausal serum androgens, oestrogens and breast cancer risk: the European prospective investigation into cancer and nutrition

  Citation: 414

  Authors: R, S, T J, F, P H M, C, L, A, S, K-T, N E, H B, C H, D, H, P H, G, J, F, A, A, C A, J R, M-J, E, P, V, D, S, R, P, A, V, D, P, T, R, E

---